Blockbuster retatrutide trial signals a ‘new high-water mark’ for weight-loss drugs
The experimental weight-loss drug is a triple agonist and the first of its kind to reach a phase 3 clinical trial
Read the full story at Scientific American ↗
ImpactNotable 33/100
Why it mattersRule-based estimate: no strong signals; trust 8/10.
RegionsGlobal
Published5 h ago (Tue, 29 Sep 2026 22:01:00 GMT)
RetrievedWed, 30 Sep 2026 00:00:56 GMT via rss
ClassifiedWed, 30 Sep 2026 00:01:17 GMT by heuristic
AuthorJackie Flynn Mogensen